Spyre Therapeutics (SYRE) Total Current Liabilities (2015 - 2026)

Spyre Therapeutics has reported Total Current Liabilities for 12 years, with the latest figure at $85.2 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 20.49% year-over-year to $85.2 million; the trailing twelve-month figure through Mar 2026 stood at $85.2 million (up 20.49% YoY), and the FY2025 full-year result was $58.7 million, up 8.56% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $85.2 million, up from $58.7 million in the prior quarter.
• The five-year high for Total Current Liabilities was $232.2 million in Q2 2023, with the low at $12.6 million in Q1 2023.
• Historically, Total Current Liabilities has averaged $53.3 million across 5 years, with a median of $44.9 million in 2023.
• Annual changes were most pronounced in 2023 — Total Current Liabilities soared 1364.09% — and 2024, when it slumped 90.47%.
• Spyre Therapeutics' Total Current Liabilities stood at $14.7 million in 2022, then jumped by 118.19% to $32.0 million in 2023, then jumped by 69.05% to $54.1 million in 2024, then gained by 8.56% to $58.7 million in 2025, then soared by 45.12% to $85.2 million in 2026.
• The last three Total Current Liabilities figures came in at $85.2 million (Q1 2026), $58.7 million (Q4 2025), and $46.3 million (Q3 2025), per Business Quant data.